During NEP inhibition by Entresto®, the uptake in the PC-3 tumors increased compared with controls (to 5.88 ± 1.47%IA/g; p < 0.0001), emphasizing the positive effect of metabolically stabilizing the circulating radioligand on tumor targeting [25]. Here, MME is linked to neoplasm.